FORA Capital’s Axsome Therapeutics AXSM Stock Holding History

FORA Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Buy	6,364 +4,914	+339%	+$1.07M	0.11%	182
2026 Q1	$245K	Sell	1,450 -4,264	-75%	-$737K	0.02%	381
2025 Q4	$740K	Buy	+5,714	New	+$798K	0.09%	249
2025 Q2	–	Sell	-7,633	Closed	-$890K	–	511
2025 Q1	$890K	Buy	+7,633	New	+$870K	0.09%	249
2024 Q4	–	Sell	-11,058	Closed	-$994K	–	394
2024 Q3	$994K	Buy	+11,058	New	+$965K	0.12%	214
2024 Q1	–	Sell	-8,907	Closed	-$709K	–	408
2023 Q4	$709K	Buy	+8,907	New	+$595K	0.06%	291
2022 Q4	–	Sell	-4,505	Closed	-$201K	–	464
2022 Q3	$201K	Sell	4,505 -11,713	-72%	-$585K	0.04%	384
2022 Q2	$621K	Buy	16,218 +7,476	+86%	+$236K	0.12%	209
2022 Q1	$350K	Buy	+8,742	New	+$271K	0.06%	354
2021 Q3	–	Sell	-786	Closed	-$53K	–	393
2021 Q2	$53K	Buy	+786	New	+$47.2K	0.01%	699
2021 Q1	–	Sell	-5,237	Closed	-$427K	–	776
2020 Q4	$427K	Buy	5,237 +4,925	+1,579%	+$368K	0.07%	319
2020 Q3	$22K	Sell	312 -6,193	-95%	-$483K	0.01%	571
2020 Q2	$535K	Buy	+6,505	New	+$501K	0.18%	145

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

FORA Capital's AXSM Position: Q2 2026 in Review

FORA Capital increased its Axsome Therapeutics (AXSM) stake by 339% in Q2 2026, buying an estimated $1.07M and bringing the position to 6,364 shares worth $1.56M. The position accounts for 0.11% of the portfolio, ranked #182.

FORA Capital first reported a position in AXSM in Q2 2020 and has held it in 13 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

FORA Capital held 6,364 shares of Axsome Therapeutics worth $1.56M as of Q2 2026.
FORA Capital bought 4,914 Axsome Therapeutics shares in Q2 2026, an estimated $1.07M.
Axsome Therapeutics made up 0.11% of FORA Capital's portfolio in Q2 2026, its #182 holding.
FORA Capital first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 13 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.